426 related articles for article (PubMed ID: 23745947)
1. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
2. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
[TBL] [Abstract][Full Text] [Related]
3. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.
Setnik B; Goli V; Levy-Cooperman N; Mills C; Shram M; Smith I
Pain Res Manag; 2013; 18(4):e55-62. PubMed ID: 23936895
[TBL] [Abstract][Full Text] [Related]
4. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
5. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
[TBL] [Abstract][Full Text] [Related]
6. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
7. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
8. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
[TBL] [Abstract][Full Text] [Related]
9. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
10. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
[TBL] [Abstract][Full Text] [Related]
11. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
[TBL] [Abstract][Full Text] [Related]
12. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
[TBL] [Abstract][Full Text] [Related]
13. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.
Webster LR; Pantaleon C; Iverson M; Smith MD; Kinzler ER; Aigner S
Pain Res Manag; 2018; 2018():7276021. PubMed ID: 29849845
[TBL] [Abstract][Full Text] [Related]
14. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
Johnson F; Setnik B
Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
[TBL] [Abstract][Full Text] [Related]
15. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
[TBL] [Abstract][Full Text] [Related]
16. Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users.
Setnik B; Sommerville KW; Pixton GC; Webster L
Curr Med Res Opin; 2019 Mar; 35(3):503-512. PubMed ID: 30293449
[TBL] [Abstract][Full Text] [Related]
17. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
[TBL] [Abstract][Full Text] [Related]
18. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510
[TBL] [Abstract][Full Text] [Related]
19. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
